Journal of Peking University(Health Sciences) >
Value of serum YKL-40 in the diagnosis of anti-MDA5-positive patients with dermatomyositis complicated with severe pulmonary injury
Received date: 2021-08-16
Online published: 2021-12-13
Supported by
Beijing Municipal Science and Technology Commission(Z191100006619012)
Objective: To investigate the value of serum and bronchoalveolar lavage fluid (BALF) chitinase-3-like-1 protein (YKL-40) in the diagnosis of anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis (DM) patients complicated with serious pulmonary injury, including rapidly progressive interstitial lung disease (RP-ILD) and pulmonary infection. Methods: Anti-MDA5 antibodies positive patients with DM who were hospitalized in the Department of Rheumatology of China-Japan Friendship Hospital from 2013 to 2018 were involved in this study. Demographic information, clinical, laboratory and imaging data were retrospectively collected. ELISA was used to detect the serum and BALF levels of YKL-40. The receiver operating characteristic (ROC) curve was drawn,and the area under ROC curve (AUC) was used to evaluate the diagnostic value of serum YKL-40 for pulmonary injury.Interstitial lung disease (ILD) was confirmed by chest high-resolution CT (HRCT). RP-ILD was defined as progressive respiratory symptoms such as dyspnea and hypoxemia within 3 months, and/or deterioration of interstitial changes or appearace of new pulmonary interstitial lesions on chest HRCT. Pulmonary infection was considered as positive pathogens detected in qualified sputum, blood, bronchoalveolar lavage fluid or lung biopsy specimens. Results: A total of 168 anti-MDA5-positive DM patients including 108 females and 60 males were enrolled in the study. Of these patients, 154 had ILD, and 66(39.3%) of them presented RP-ILD. Seventy patients with pulmonary infection were confirmed by etiology. In the patients with RP-ILD, 39 (59.1%) of them were complicated with pulmonary infection. While only 31 cases(30.4%) had pulmonary infection in the non-RP-ILD patients. The incidence of pulmonary infection in the patients with RP-ILD was significantly higher than that of those with non-RP-ILD (P<0.001). The serum YKL-40 levels in the RP-ILD patients with pulmonary infection were the highest compared with RP-ILD without pulmonary infection, non-RP-ILD with pulmonary infection and non-RP-ILD without pulmonary infection groups among all the patients [83 (42-142) vs. 42 (21-91) vs. 43 (24-79) vs. 38 (22-69), P<0.01].The sensitivity, specificity and AUC of serum YKL-40 in the diagnosis of RP-ILD complicated with pulmonary infection were 75%, 67%, and 0.72, respectively. The AUC of diagnosed of anti-MDA5 positive DM patients complicated with RP-ILD and pulmonary infection was higher than that of patients complicated with only RP-ILD and only pulmonary infection (0.72 vs. 0.54 and 0.55, Z=2.10 and 2.11, P<0.05). Conclusion: The prognosis of anti-MDA5-positive DM patients with RP-ILD and pulmonary infection were poor. Serum YKL-40 level can be used as a helpful tool for the diagnosis of coexistence of these conditions in the patients.
Pu-li ZHANG , Hong-xia YANG , Li-ning ZHANG , Yong-peng GE , Qing-lin PENG , Guo-chun WANG , Xin LU . Value of serum YKL-40 in the diagnosis of anti-MDA5-positive patients with dermatomyositis complicated with severe pulmonary injury[J]. Journal of Peking University(Health Sciences), 2021 , 53(6) : 1055 -1060 . DOI: 10.19723/j.issn.1671-167X.2021.06.008
| [1] | Gupta R, Kumar S, Gow P, et al. Anti-MDA5-associated dermatomyositis[J]. Intern Med J, 2020, 50(4):484-487. |
| [2] | Lian X, Zou J, Guo Q, et al. Mortality risk prediction in amyopathic dermatomysitis associated with interstitial lung disease: The FLAIR model[J]. Chest, 2020, 158(4):1535-1545. |
| [3] | Ge YP, Shu XM, He LR, et al. Infection is not rare in patients with idiopathic inflammatory myopathies[J/OL]. Clin Exp Rheumatol, 2021(2021-07-21)[2021-08-01]. https://pubmed.ncbi.nlm.nih.gov/34369354/. |
| [4] | Wu C, Wang Q, He L, et al. Hospitalization mortality and associated risk factors in patients with polymyositis and dermatomyositis: A retrospective case-control study[J]. PLoS One, 2018, 13(2):e0192491. |
| [5] | Yeo IJ, Lee CK, Han SB, et al. Roles of chitinase 3-like 1 in the development of cancer, neurodegenerative diseases, and inflammatory diseases[J/OL]. Pharmacol Ther, 2019, 203(2019-07-26)[2021-08-01]. https://doi.org/10.1016/j.pharmthera.2019.107394. |
| [6] | Furuhashi K, Suda T, Nakamura Y, et al. Increased expression of YKL-40, a chitinase-like protein, in serum and lung of patients with idiopathic pulmonary fibrosis[J]. Respir Med, 2010, 104(8):1204-1210. |
| [7] | Kornblit B, Hellemann D, Munthe-Fog L, et al. Plasma YKL-40 and CHI3L1 in systemic inflammation and sepsis-experience from two prospective cohorts[J]. Immunobiology, 2013, 218(10):1227-1234. |
| [8] | Spoorenberg SM, Vestjens SM, Rijkers GT, et al. YKL-40, CCL18 and SP-D predict mortality in patients hospitalized with community-acquired pneumonia[J]. Respirology, 2017, 22(3):542-550. |
| [9] | Hozumi H, Fujisawa T, Enomoto N, et al. Clinical utility of YKL-40 in polymyositis/dermatomyositis-associated interstitial lung disease[J]. J Rheumatol, 2017, 44(9):1394-1401. |
| [10] | Jiang L, Wang Y, Peng Q, et al. Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody[J]. Clin Rheumatol, 2019, 38(6):1655-1663. |
| [11] | Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups[J]. Ann Rheum Dis, 2017, 76(12):1955-1964. |
| [12] | Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias[J]. Am J Respir Crit Care Med, 2013, 188(6):733-748. |
| [13] | Moghadam-Kia S, Oddis CV, Aggarwal R. Anti-MDA5 antibody spectrum in western world[J]. Curr Rheumatol Rep, 2018, 20(12):78. |
| [14] | Sugiyama Y, Yoshimi R, Tamura M, et al. The predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial lung disease[J]. Arthritis Res Ther, 2018, 20(1):7. |
| [15] | James AJ, Reinius LE, Verhoek M, et al. Increased YKL-40 and chitotriosidase in asthma and chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2016, 193(2):131-142. |
| [16] | Korthagen NM, van Moorsel CH, Barlo NP, et al. Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis[J]. Respir Med, 2011, 105(1):106-113. |
| [17] | Fantino E, Gangell CL, Hartl D, et al. Airway, but not serum or urinary, levels of YKL-40 reflect inflammation in early cystic fibrosis lung disease[J/OL]. BMC Pulm Med, 2014, 14: 28[2021-08-01]. https://doi.org/10.1186/1471-2466-14-28. |
| [18] | Wang HL, Hsiao PC, Tsai HT, et al. Usefulness of plasma YKL-40 in management of community-acquired pneumonia severity in patients[J]. Int J Mol Sci, 2013, 14(11):22817-22825. |
| [19] | Yang X, Sheng G. YKL-40 levels are associated with disease severity and prognosis of viral pneumonia, but not available in bacterial pneumonia in children[J]. BMC Pediatr, 2018, 18(1):381. |
| [20] | Long X, Xuan H, Ohshimo S, et al. Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis[J/OL]. Eur Respir J, 2016, 49(2): 1501924 [2021-08-01]. https://doi.org/10.1183/13993003.01924-2015. |
| [21] | Shirakashi M, Nakashima R, Tsuji H, et al. Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment[J]. Rheumatology (Oxford), 2020, 59(11):3284-3292. |
/
| 〈 |
|
〉 |